Skip to content
Research Article Open access CC BY 4.0

ASpirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG): A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

Ahmad M. Slim, Emilio Fentanes, Dustin M. Thomas, Jennifer N. Slim, Taylor Triana, Homayoun R. Ahmadian, Ryan J. McDonough, Jason Saucedo, Norma J. Suarez, Dorette Pearce-Moore, H. Lester Kirchner, Edward Hulten, Ricardo C. Cury, Kelley Branch

Journal of Advances in Medicine and Medical Research · pp. 1–10 · Published 2 Mar 2016

10.9734/BJMMR/2016/24386

Abstract

Background: Vein graft thrombosis is the leading cause of acute graft failure within the first post-operative month. Several studies have shown the benefit of post-operative dual anti-platelet therapy (DAPT) in preventing acute graft thrombosis. The purpose of this study was to determine whether peri-operative initiation of DAPT will improve short and intermediate term graft patency. Methods: This was a randomized, double-blind, placebo controlled trial of 20 patients undergoing CABG to compare DAPT versus aspirin monotherapy. The primary outcome was post-operative graft patency at 2 and 52 weeks determined by <50% bypass graft stenosis by cardiac computed tomography angiography (CCTA). The secondary outcomes were (1) major adverse cardiovascular events (MACE), defined as myocardial infarction, thrombotic events, and angina, and (2) safety end-points defined as TIMI major and minor bleeding events. Results: The study population consisted predominately of men (19/20 patients). At 2 weeks, all LIMA grafts were patent although vein graft patency for the DAPT group was only 83.3% (20/24) compared to 89.5% (17/19) for placebo (p=0.597). At 52 weeks, the patency rate in the placebo group was 52.6% (10/19) as compared to a patency of 71.4% (15/24) in the dual anti-platelet therapy arm (p=0.244).  Conclusion: The addition of clopidogrel to aspirin post-bypass surgery did not significantly improve venous graft patency at 2 weeks but trended toward higher graft patency at 52 weeks.

Aspirin Plavix CCTA coronary artery bypass surgery graft patency major adverse cardiovascular events

Cited by 10

Meta-Analysis of Aspirin Versus Dual Antiplatelet Therapy Following Coronary Artery Bypass Grafting

Nayan Agarwal, Ahmed N. Mahmoud, Nimesh Kirit Patel · The American Journal of Cardiology · 2018

Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis

Saurabh Gupta, Emilie P Belley-Cote, Puru Panchal · Interactive CardioVascular and Thoracic Surgery · 2020

Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis

Rhanderson Cardoso, Leonardo Knijnik, Seamus P. Whelton · International Journal of Cardiology · 2018

Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events

Alessandro Squizzato, Marta Bellesini, Andrea Takeda · Cochrane Database of Systematic Reviews · 2017

Ticagrelor-based antiplatelet regimens in patients treated with coronary artery bypass grafting: a meta-analysis of randomized controlled trials

Moritz von Scheidt, Dario Bongiovanni, Ulrich Tebbe · European Journal of Cardio-Thoracic Surgery · 2019

Showing 9 of 10 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

10

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.